Autres langues Entera Bio Ltd.

Actions

ENTX

IL0011429839

Temps réel estimé Cboe BZX Autres places de cotation 21:32:27 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,925 ^USD	+2,94 %		+7,46 %	+222,37 %

15/05	Entera Bio nomme Rachel B. Wagman conseillère clinique principale et membre du conseil scientifique	CI
13/05	Entera Bio présentera les données de phase 1 des comprimés de peptide PTH(1-34), premier de sa classe (EB612), pour le traitement de l'hypoparathyroïdie à ENDO 2024.	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024	03/06
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	15/05
Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	15/05
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024	13/05
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	13/05
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates	10/05
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	26/03
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	26/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	08/03
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	04/03
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30/01
Top Premarket Gainers	18/01
Top Premarket Gainers	17/01
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Entera Bio Ltd.

Actions

ENTX

IL0011429839

Autres langues

Filtres